Fabrazyme ® 35mg (agalsidase beta)
Product details
Registration number: SIN13609P
Classification: Prescription Only
Active ingredients: Agalsidase beta
Strength: 37.0mg/35mg vial
Dosage form: INJECTION, POWDER, FOR SOLUTION
Route: INTRAVENOUS
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
ATC code: A16AB04
HSA approval date: 10 March 2009
Manufacturer(s): Genzyme Ireland Limited
Manufacturing country/countries: IRELAND
What are the HSA registration number and classification for Fabrazyme ® 35mg (agalsidase beta)?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN13609P
Classification: Prescription Only
What active ingredients and strength are recorded for Fabrazyme ® 35mg (agalsidase beta)?
According to the HSA dataset updated 7 August 2026:
Active ingredients: Agalsidase beta
Strength: 37.0mg/35mg vial
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for Fabrazyme ® 35mg (agalsidase beta)?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, POWDER, FOR SOLUTION
Route: INTRAVENOUS
Who is the recorded registrant for Fabrazyme ® 35mg (agalsidase beta)?
According to the HSA dataset updated 7 August 2026:
Registrant: SANOFI-AVENTIS SINGAPORE PTE. LTD.
Which manufacturers and countries are listed for Fabrazyme ® 35mg (agalsidase beta)?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s): Genzyme Ireland Limited
Manufacturing country/countries: IRELAND
Where can I look up Fabrazyme ® 35mg (agalsidase beta) in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN13609P or the exact product name Fabrazyme ® 35mg (agalsidase beta). The general register link does not preselect this product.
What are the source dates for this Fabrazyme ® 35mg (agalsidase beta) record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this Fabrazyme ® 35mg (agalsidase beta) record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN13609P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)